Inovio Pharmaceuticals Inc INO

US Biotechnology

$0.68 ▲ +3.20% (+$0.02)

🗓️ Earnings Next Week

Open $0.65

Prev Close $0.66

Day Range $0.62 – $0.68

52W Range $0.56 – $2.98

Market Cap $55.70M

Beta 1.53

EPS (TTM) $-1.70

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1998-12-08
Shares Out.	82,270,000
Website	inovio.com/ ↗
Phone	13026587581
Employees	112
Net Income	-$19.7M
Free Cash Flow	-$83.6M
Total Assets	$49.8M
Total Liabilities	$43.7M
Equity	$6.1M

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.

Inovio Pharmaceuticals Inc is a publicly traded company under the ticker symbol INO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.